Thus, a combined approach targeting TGF-β signaling through LY2157299 and inhibiting endogenous ANGPTL4 expression would be a sensible therapeutic strategy for CRC peritoneal metastasis. This evidence concerns the gene TGFB1 and colorectal carcinoma.